ADMA Biologics Inc

Company Profile

ADMA Biologics Inc had its IPO on 2013-10-17 under the ticker symbol ADMA.

The company operates in the Healthcare sector and Biotechnology industry. ADMA Biologics Inc has a staff strength of 527 employees.

Stock update

Shares of ADMA Biologics Inc opened at $3.13 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $3.03 - $3.18, and closed at $3.1.

This is a -0.96% slip from the previous day's closing price.

A total volume of 9,980,400 shares were traded at the close of the day’s session.

In the last one week, shares of ADMA Biologics Inc have slipped by -5.49%.

ADMA Biologics Inc's Key Ratios

ADMA Biologics Inc has a market cap of $751.07 million, indicating a price to book ratio of 7.7007 and a price to sales ratio of 5.9412.

In the last 12-months ADMA Biologics Inc’s revenue was $130.48 million with a gross profit of $1.17 million and an EBITDA of $-39803512. The EBITDA ratio measures ADMA Biologics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, ADMA Biologics Inc’s operating margin was -35.64% while its return on assets stood at -10.78% with a return of equity of -69.23%.

In Q3, ADMA Biologics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 98.7%.

ADMA Biologics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.33 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ADMA Biologics Inc’s profitability.

ADMA Biologics Inc stock is trading at a EV to sales ratio of 6.2567 and a EV to EBITDA ratio of -17.4554. Its price to sales ratio in the trailing 12-months stood at 5.9412.

ADMA Biologics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$300.56 million

Total Liabilities

$44.44 million

Operating Cash Flow

$-3380481.00

Capital Expenditure

$6.22 million

Dividend Payout Ratio

0%

ADMA Biologics Inc ended 2023 with $300.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $300.56 million while shareholder equity stood at $100.38 million.

ADMA Biologics Inc ended 2023 with $0 in deferred long-term liabilities, $44.44 million in other current liabilities, 19678.00 in common stock, $-465784988.00 in retained earnings and $3.53 million in goodwill. Its cash balance stood at $34.91 million and cash and short-term investments were $34.91 million. The company’s total short-term debt was $720,755 while long-term debt stood at $141.37 million.

ADMA Biologics Inc’s total current assets stands at $224.09 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $20.90 million compared to accounts payable of $25.20 million and inventory worth $162.91 million.

In 2023, ADMA Biologics Inc's operating cash flow was $-3380481.00 while its capital expenditure stood at $6.22 million.

Comparatively, ADMA Biologics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$3.1

52-Week High

$3.98

52-Week Low

$1.43

Analyst Target Price

$5.13

ADMA Biologics Inc stock is currently trading at $3.1 per share. It touched a 52-week high of $3.98 and a 52-week low of $3.98. Analysts tracking the stock have a 12-month average target price of $5.13.

Its 50-day moving average was $3.5 and 200-day moving average was $2.86 The short ratio stood at 4.72 indicating a short percent outstanding of 0%.

Around 170% of the company’s stock are held by insiders while 7770.2% are held by institutions.